Akrevia launches with $30M in Series A financing
The company, with ARIAD and Intellia veterans at the helm, aims to develop CTLA4-targeting monoclonal antibody that mitigates the immune toxicity of Bristol's Yervoy.
7 key ingredients in Celgene’s recipe for biopharma dealmaking
Here are the “seven habits”, or more aptly just attributes, of Celgene’s highly successful external R&D strategy.
presented by
A lesson on biotech CEO dynamics using… thermodynamics!
Venture capitalist Bruce Booth likened CEO dynamics to thermodynamics in a blog that uses scientific parlance to describe leadership challenges to the nerdy biotech set. The metaphors are pretty out of control. Explosive? For instance, as in thermodynamic reactions, Booth asserts there are two kinds of CEOs – exothermic (energy releasing) and endothermic (energy absorbing). The exothermic CEO is […]